TrialBMC cancer2019

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.

Yoshihiko Tomita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.